Local heterogeneity of normal lung parenchyma and small airways disease are associated with COPD severity and progression

正常肺实质的局部异质性和小气道疾病与慢性阻塞性肺疾病的严重程度和进展相关。

阅读:1

Abstract

BACKGROUND: Small airways disease (SAD) is a major cause of airflow obstruction in COPD patients and has been identified as a precursor to emphysema. Although the amount of SAD in the lungs can be quantified using our Parametric Response Mapping (PRM) approach, the full breadth of this readout as a measure of emphysema and COPD progression has yet to be explored. We evaluated topological features of PRM-derived normal parenchyma and SAD as surrogates of emphysema and predictors of spirometric decline. METHODS: PRM metrics of normal lung (PRM(Norm)) and functional SAD (PRM(fSAD)) were generated from CT scans collected as part of the COPDGene study (n = 8956). Volume density (V) and Euler-Poincaré Characteristic (χ) image maps, measures of the extent and coalescence of pocket formations (i.e., topologies), respectively, were determined for both PRM(Norm) and PRM(fSAD). Association with COPD severity, emphysema, and spirometric measures were assessed via multivariable regression models. Readouts were evaluated as inputs for predicting FEV(1) decline using a machine learning model. RESULTS: Multivariable cross-sectional analysis of COPD subjects showed that V and χ measures for PRM(fSAD) and PRM(Norm) were independently associated with the amount of emphysema. Readouts χ(fSAD) (β of 0.106, p < 0.001) and V(fSAD) (β of 0.065, p = 0.004) were also independently associated with FEV(1)% predicted. The machine learning model using PRM topologies as inputs predicted FEV(1) decline over five years with an AUC of 0.69. CONCLUSIONS: We demonstrated that V and χ of fSAD and Norm have independent value when associated with lung function and emphysema. In addition, we demonstrated that these readouts are predictive of spirometric decline when used as inputs in a ML model. Our topological PRM approach using PRM(fSAD) and PRM(Norm) may show promise as an early indicator of emphysema onset and COPD progression.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。